Neuronetics to Shine at Major Industry Conference
Neuronetics, Inc. (NASDAQ: STIM), known for its transformative impact in the field of neurohealth, has exciting news to share. The company's President and Chief Executive Officer, Keith Sullivan, is set to present at a prominent upcoming event, the Canaccord Genuity 45th Annual Growth Conference. This significant gathering will take place on a Tuesday in August.
The Importance of Neurohealth Solutions
At Neuronetics, the commitment to neurohealth goes beyond merely providing treatments; it reflects a broader vision of improving patients' lives. As the world increasingly recognizes the critical importance of mental health, Neuronetics stands out by delivering effective, non-invasive, and patient-centered treatment solutions. One such groundbreaking therapy offered is the NeuroStar Advanced Therapy, which has proven successful in helping individuals who struggle with conditions that traditional medications have not sufficiently addressed.
Impact of NeuroStar Advanced Therapy
Neuronetics' NeuroStar Advanced Therapy is a non-drug solution designed to enhance the quality of life for those suffering from various neurohealth conditions. This therapy is a noninvasive option to aid individuals battling major depressive disorder (MDD) and provides a sense of hope where conventional methods may have faltered. With over 7.4 million treatments administered, NeuroStar is backed by the largest clinical dataset of any TMS treatment system, ensuring unparalleled effectiveness and safety.
An Expanding Network of Treatment Centers
The company also manages Greenbrook TMS Inc. treatment centers throughout the nation. These facilities not only offer NeuroStar Advanced Therapy for MDD but also treat other mental health disorders, catering to a growing number of patients in need. This extensive network has successfully provided over 1.8 million treatments, uplifting more than 55,000 individuals facing depression.
Safety and Efficacy
The NeuroStar Advanced Therapy System holds FDA clearance for treating adults with major depressive disorder. It serves as an adjunctive treatment for various conditions, including obsessive-compulsive disorder and anxiety-related symptoms. This multifaceted approach ensures comprehensive care for patients, including adolescents aged 15-21. For more information about safety guidelines and approved uses, visit the official NeuroStar website.
Looking Towards the Future
As the company prepares for its presentation at the conference, it emphasizes its dedication to pioneering innovation in the neurohealth sector. Neuronetics is not just a company; it is a movement towards better mental health solutions worldwide. The upcoming event is an opportunity for Neuronetics to showcase how it can further impact patients' lives, reflecting its commitment and advancements in this crucial area.
Connect with Neuronetics
For investors interested in learning more, Neuronetics provides accessible information through several channels. Investors can reach out to Mike Vallie or Mark Klausner at ICR Healthcare for inquiries. Moreover, the team is committed to transparent communication, as evidenced by their readily available contact information, making them approachable for those seeking more details.
Media Inquiries
For media-related requests, EvolveMKD is the designated contact point. Their expertise ensures that all inquiries are handled efficiently, allowing Neuronetics to maintain a strong public presence and engage with the media effectively.
Frequently Asked Questions
What is the NeuroStar Advanced Therapy?
The NeuroStar Advanced Therapy is a non-invasive, drug-free treatment designed to improve the quality of life for people battling major depressive disorder and other mental health issues.
How does Neuronetics support mental health?
Neuronetics offers advanced therapeutic options and operates treatment centers to deliver effective care and support to individuals suffering from mental health disorders.
What will be discussed at the conference?
Keith Sullivan will present the innovations and clinical successes of Neuronetics, highlighting their impact on the mental health sector and patient care.
Is NeuroStar Advanced Therapy FDA cleared?
Yes, the NeuroStar Advanced Therapy System is FDA cleared for multiple indications, including treatment-resistant depression and for use in adolescents.
How can I contact Neuronetics for more information?
For inquiries, you can reach out to Neuronetics via their investor relations contact or through EvolveMKD for media inquiries.
